Enliven Therapeutics (NASDAQ:ELVN) Trading Down 3% After Insider Selling

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s stock price dropped 3% on Thursday after an insider sold shares in the company. The company traded as low as $17.90 and last traded at $18.08. Approximately 11,209 shares traded hands during trading, a decline of 92% from the average daily volume of 135,877 shares. The stock had previously closed at $18.63.

Specifically, CEO Samuel Kintz sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $17.56, for a total transaction of $210,720.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Enliven Therapeutics news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $15.00, for a total transaction of $7,500,000.00. Following the completion of the transaction, the insider now owns 771,983 shares of the company’s stock, valued at $11,579,745. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Samuel Kintz sold 12,000 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.56, for a total transaction of $210,720.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 593,318 shares of company stock valued at $8,983,658. 45.80% of the stock is owned by corporate insiders.

Enliven Therapeutics Trading Down 2.9 %

The firm has a market cap of $745.31 million, a P/E ratio of -8.51 and a beta of 1.05. The business has a 50-day moving average of $15.83 and a two-hundred day moving average of $13.84.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after buying an additional 1,029 shares during the period. Deutsche Bank AG grew its holdings in Enliven Therapeutics by 16.7% in the third quarter. Deutsche Bank AG now owns 10,890 shares of the company’s stock worth $149,000 after purchasing an additional 1,559 shares during the period. Legal & General Group Plc increased its stake in Enliven Therapeutics by 8.9% in the third quarter. Legal & General Group Plc now owns 19,665 shares of the company’s stock valued at $269,000 after purchasing an additional 1,610 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in shares of Enliven Therapeutics during the 1st quarter worth about $36,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Enliven Therapeutics by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 158,440 shares of the company’s stock valued at $2,193,000 after buying an additional 1,809 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.